| Name | Silmitasertib sodium salt |
| Description | Silmitasertib sodium salt (CX-4945 sodium salt) is a potent and orally bioavailable, highly selective inhibitor of CK2(IC50 of 1 nM, CK2α). |
| In vitro | Silmitasertib induces cytotoxicity and apoptosis, and exerts anti-proliferative effects in hematological tumors by downregulating CK2 expression and suppressing activation of CK2-mediated PI3K/Akt/mTOR signaling pathways[3]. Silmitasertib (CX-4945) resultes in cell-cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells, attenuates PI3K/Akt signalingand. The antiproliferative activity of Silmitasertib is correlated with expression levels of the CK2α catalytic subunit, attenuation of PI3K/Akt signaling[1]. Silmitasertib with PS-341 treatment prevents leukemic cells from engaging a functional UPR in order to buffer the PS-341-mediated proteotoxic stress in ER lumen, and decreases pro-survival ER chaperon BIP/Grp78 expression[2]. |
| In vivo | Silmitasertib (CX-4945), administered at doses of 25 or 75 mg/kg orally, was well tolerated and demonstrated strong antitumor effects alongside significant decreases in the mechanistic biomarker phospho-p21 (T145) in murine xenograft models[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 12.5 mg/mL (33.62 mM), Sonication is recommended.
DMSO : 38.33 mg/mL (103.11 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (10.76 mM), Sonication is recommended.
|
| Keywords | Silmitasertib sodium salt | Silmitasertib sodium | Silmitasertib | Inhibitor | inhibit | CX-4945 sodium | CX-4945 | CX4945 | CX 4945 | CK2α' | CK2α | CK2 | CaseinKinase | Casein Kinase | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Enzalutamide | Paeonol | Naringin | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Endoplasmic Reticulum Stress Compound Library | Membrane Protein-targeted Compound Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
